PerezRArchdeaconPRoachN. Sponsors’ and investigative staff’s perceptions of the current investigational new drug safety reporting process in oncology trials. Clin Trials, in press.
2.
JarowJPCasakSChukM. The majority of expedited investigational new drug safety reports are uninformative. Clin Cancer Res2016; 22: 2111–2113.
3.
CavnarSValenciaPBrockJ. The immuno-oncology race: myths and emerging realities. Nat Rev Drug Discov2017; 16: 83–84.
4.
RobbMARacoosinJAShermanRE. The US Food and Drug Administration’s Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf2012; 21(Suppl. 1): 9–11.
5.
BehrmanREBennerJSBrownJS. Developing the Sentinel System—a national resource for evidence development. N Engl J Med2011; 364: 498–499.
6.
KhozinSKimGPazdurR.Regulatory watch: from big data to smart data: FDA’s INFORMED initiative. Nat Rev Drug Discov. Epub ahead of print 24 February 2017. DOI: 10.1038/nrd.2017.26.
7.
KhozinSChukMKimT. Regulatory watch: evaluating the potential for digital submission of expedited premarket safety reports to the FDA. Nat Rev Drug Discov2016; 15: 670–671.
